$CRVO

BOGER JOSHUA S purchased $3.0M of CRVO (indirect holdings)

BOGER JOSHUA S purchased 955,414 indirectly-held shares of CervoMed Inc. (CRVO) at $3.14 ($3.00M total) on 2026-06-11.

Original reporting
SEC EDGAR · BOGER JOSHUA S
Published Jun 15, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRVO
Neutral
medium confidence
Mentioned
$CRVO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRVONeutralLow
01

Why it matters

A director and 10% owner purchased $3.0M of shares at $3.14/share (indirect holdings), with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may treat the insider buy as a mild sentiment input, but the filing alone is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The filing does not disclose any accompanying operational or clinical catalyst; without follow-on company news, traders may overreact to the insider signal.

Relevance 7/10Novelty 5/10Timing: filed 2026-06-15, transaction dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for CervoMed Inc. (CRVO).

Company-level read

Ticker impact

$CRVONeutralMedium confidence
Context

CervoMed director and 10% owner BOGER JOSHUA S bought 955,414 shares in an open-market transaction worth about $3.0M.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and modest.

Evidence & confidence

Form 4 provides a fresh, primary-source transaction, but insider buys without accompanying company-specific catalysts typically do not reset valuation expectations.

Market effects

No sector-wide implications disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The buy is indirect and not under a 10b5-1 plan, so it may reflect personal liquidity or estate structuring rather than a strong forward view.

Key entities

  • CervoMed Inc.

    Subject of the Form 4 insider transaction disclosure.

  • BOGER JOSHUA S

    Director and 10% owner who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRVOMedAI 8/10

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a…

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 On average, reduction in plasma neu

$CRVOMedAI 8/10

CervoMed reports biomarker decline in dementia trial

CervoMed Inc. (CRVO) reported a 3.1 pg/mL reduction in plasma NfL levels in a 12-week Phase 2a trial of neflamapimod for nfvPPA, a form of frontotemporal dementia. The study involved 25 participants, with 18 having elevated baseline NfL levels. The company plans to present 24-week data in November 2026 and topline clinical data in Q1 2027. No treatments are currently approved for nfvPPA in the U.S. or EU.